FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212773239> ?p ?o ?g. }

• W4212773239 endingPage "367" @default.
• W4212773239 startingPage "367" @default.
• W4212773239 abstract "367 Background: Despite promising therapeutic efficacy of immune checkpoint inhibitors in renal cell carcionoma (RCC) response varies significantly between individual patients. Therefore, predictors of response are urgently needed. To identify novel predictive biomarkers, we explored the characteristics of blood-circulating immune cell subsets within the population of the TITAN-RCC trial (NCT02917772) applying a tailored approach with nivolumab (nivo) and ipilimumab (ipi). Methods: In TITAN-RCC, patients with intermediate and poor risk advanced clear cell RCC started nivo Q2W induction. Upon early progressive disease (PD, week 8) or non-response (stable disease or PD) at week 16, patients received 2-4 nivo+ipi “boost” cycles. Responders (complete or partial response) to nivo induction continued with maintenance but could receive nivo+ipi for later PD. Blood samples for biomarker analyses were taken at baseline, during nivo induction and nivo+ipi “boost” cycles. Samples from 198 RCC patients (105 first line, 93 second line) were analyzed by multi-parametric flow cytometry for frequency and phenotype of T cell, monocyte, myeloid-derived suppressor cell (MDSC) and dendritic cell (DC) subsets. Baseline data were associated to response upon nivo induction and data from samples taken prior to first “boost” to response to nivo+ipi. We applied uni- and multivariable logistic regression modelling to investigate the association between treatment response and immune parameters. Here we report on single marker models (adjusted for age and gender). Results: Higher percentages of blood-circulating 4-1BB+ CD4+ T cells (adjusted odds ratio (OR adj ) 1.05, 95% CI 1.02-1.08), 4-1BB+ CD8+ T cells (OR adj 1.03, 95% CI 1.01-1.07) and LAG3+ CD4+ T cells (OR adj 1.03, 95% CI 1.01-1.05) were found in responders to nivo induction compared to non-responders. Moreover, in patients receiving nivo+ipi “boosts”, a higher proportion of PD-L1+ CD14+ monocytes (OR adj 1.22, 95% CI 1.06-1.58), PD-L1+ early-stage MDSC (OR adj 1.14, 95% CI 1.02-1.41) and PD-L1+ plasmacytoid DC (OR adj 1.08, 95% CI 1.01-1.17) was observed in responders compared to non-responders. Conclusions: We identified various immune cell-related parameters that are associated with increased or poor therapeutic efficacy in RCC patients which are currently investigated in multi-marker models. These parameters may represent novel predictive biomarkers for response to nivo±ipi in clear cell RCC. Clinical trial information: NCT02917772." @default.
• W4212773239 created "2022-02-24" @default.
• W4212773239 creator A5000830406 @default.
• W4212773239 creator A5002106647 @default.
• W4212773239 creator A5006337629 @default.
• W4212773239 creator A5009638221 @default.
• W4212773239 creator A5013173067 @default.
• W4212773239 creator A5017439917 @default.
• W4212773239 creator A5020564736 @default.
• W4212773239 creator A5028800604 @default.
• W4212773239 creator A5030902321 @default.
• W4212773239 creator A5036620887 @default.
• W4212773239 creator A5040102918 @default.
• W4212773239 creator A5041861170 @default.
• W4212773239 creator A5054850662 @default.
• W4212773239 creator A5064375340 @default.
• W4212773239 creator A5070006234 @default.
• W4212773239 creator A5071928750 @default.
• W4212773239 creator A5071984747 @default.
• W4212773239 creator A5074162105 @default.
• W4212773239 creator A5077524499 @default.
• W4212773239 creator A5087443427 @default.
• W4212773239 date "2022-02-20" @default.
• W4212773239 modified "2023-10-18" @default.
• W4212773239 title "Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial." @default.
• W4212773239 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.367" @default.
• W4212773239 hasPublicationYear "2022" @default.
• W4212773239 type Work @default.
• W4212773239 citedByCount "0" @default.
• W4212773239 crossrefType "journal-article" @default.
• W4212773239 hasAuthorship W4212773239A5000830406 @default.
• W4212773239 hasAuthorship W4212773239A5002106647 @default.
• W4212773239 hasAuthorship W4212773239A5006337629 @default.
• W4212773239 hasAuthorship W4212773239A5009638221 @default.
• W4212773239 hasAuthorship W4212773239A5013173067 @default.
• W4212773239 hasAuthorship W4212773239A5017439917 @default.
• W4212773239 hasAuthorship W4212773239A5020564736 @default.
• W4212773239 hasAuthorship W4212773239A5028800604 @default.
• W4212773239 hasAuthorship W4212773239A5030902321 @default.
• W4212773239 hasAuthorship W4212773239A5036620887 @default.
• W4212773239 hasAuthorship W4212773239A5040102918 @default.
• W4212773239 hasAuthorship W4212773239A5041861170 @default.
• W4212773239 hasAuthorship W4212773239A5054850662 @default.
• W4212773239 hasAuthorship W4212773239A5064375340 @default.
• W4212773239 hasAuthorship W4212773239A5070006234 @default.
• W4212773239 hasAuthorship W4212773239A5071928750 @default.
• W4212773239 hasAuthorship W4212773239A5071984747 @default.
• W4212773239 hasAuthorship W4212773239A5074162105 @default.
• W4212773239 hasAuthorship W4212773239A5077524499 @default.
• W4212773239 hasAuthorship W4212773239A5087443427 @default.
• W4212773239 hasConcept C121608353 @default.
• W4212773239 hasConcept C126322002 @default.
• W4212773239 hasConcept C143998085 @default.
• W4212773239 hasConcept C185592680 @default.
• W4212773239 hasConcept C203014093 @default.
• W4212773239 hasConcept C2775949291 @default.
• W4212773239 hasConcept C2777701055 @default.
• W4212773239 hasConcept C2780030458 @default.
• W4212773239 hasConcept C2780851360 @default.
• W4212773239 hasConcept C2781197716 @default.
• W4212773239 hasConcept C2781433595 @default.
• W4212773239 hasConcept C2908647359 @default.
• W4212773239 hasConcept C55493867 @default.
• W4212773239 hasConcept C71924100 @default.
• W4212773239 hasConcept C8891405 @default.
• W4212773239 hasConcept C99454951 @default.
• W4212773239 hasConceptScore W4212773239C121608353 @default.
• W4212773239 hasConceptScore W4212773239C126322002 @default.
• W4212773239 hasConceptScore W4212773239C143998085 @default.
• W4212773239 hasConceptScore W4212773239C185592680 @default.
• W4212773239 hasConceptScore W4212773239C203014093 @default.
• W4212773239 hasConceptScore W4212773239C2775949291 @default.
• W4212773239 hasConceptScore W4212773239C2777701055 @default.
• W4212773239 hasConceptScore W4212773239C2780030458 @default.
• W4212773239 hasConceptScore W4212773239C2780851360 @default.
• W4212773239 hasConceptScore W4212773239C2781197716 @default.
• W4212773239 hasConceptScore W4212773239C2781433595 @default.
• W4212773239 hasConceptScore W4212773239C2908647359 @default.
• W4212773239 hasConceptScore W4212773239C55493867 @default.
• W4212773239 hasConceptScore W4212773239C71924100 @default.
• W4212773239 hasConceptScore W4212773239C8891405 @default.
• W4212773239 hasConceptScore W4212773239C99454951 @default.
• W4212773239 hasIssue "6_suppl" @default.
• W4212773239 hasLocation W42127732391 @default.
• W4212773239 hasOpenAccess W4212773239 @default.
• W4212773239 hasPrimaryLocation W42127732391 @default.
• W4212773239 hasRelatedWork W2760849249 @default.
• W4212773239 hasRelatedWork W2799455970 @default.
• W4212773239 hasRelatedWork W2885614177 @default.
• W4212773239 hasRelatedWork W3101025619 @default.
• W4212773239 hasRelatedWork W3119432592 @default.
• W4212773239 hasRelatedWork W3134228898 @default.
• W4212773239 hasRelatedWork W3170189973 @default.
• W4212773239 hasRelatedWork W3215044659 @default.
• W4212773239 hasRelatedWork W4292373623 @default.
• W4212773239 hasRelatedWork W4292624339 @default.
• W4212773239 hasVolume "40" @default.
• W4212773239 isParatext "false" @default.

• next